RMRyan Murchie

Ryan Murchie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ryan Murchie has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Aleixo M. Muise

    Department of Paediatrics, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children University of Toronto Toronto Ontario Canada

    3 shared publications
  • Abdul Elkadri

    Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children, Toronto, ON

    2 shared publications
  • Adi Ovadia

    Division of Immunology and Allergy, The Canadian Centre for Primary Immunodeficiency, The Hospital for Sick Children and The University of Toronto, Toronto, ON

    2 shared publications
  • Amit Nahum

    Pediatrics A, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of The Negev, Israel

    2 shared publications
  • Cornelia Thoeni

    Division of Gastroenterology, Hepatology, and Nutrition, The Hospital for Sick Children, Toronto, ON

    2 shared publications
  • Ernest Cutz

    Division of Pathology, The Hospital for Sick Children, Toronto, ON

    2 shared publications

Latest Publications

  • The effects of STAT1 dysfunction on the gut

    by Cornelia Thoeni, Ellen A. Hamilton, Abdul Elkadri, Ryan Murchie, Karoline Fiedler, Adi Ovadia, Nigel Sharfe, Bo Ngan, Ernest Cutz, Amit Nahum, et al.

    Introduction: Mutations in the signal transducer and activator of transcription1 (STAT1) have been associated with a variety of clinical patterns. Interestingly patients with heterozygous mutations in the DNA binding domain (DBD) of STAT1 suffer acute and chronic colitis. Methods: To further analyze the role of STAT1 deficiency in intestinal inflammation, we employed protein expression analysis of total and activated STAT1 in intestinal biopsy samples from 2 patients with heterozygous mutations in the DBD of the STAT1 gene. Results: Both patients showed clinical and histological features of colitis. Total and activated STAT1 were decreased in duodenal and colonic enterocytes, and total STAT1 was found to be mislocalized in aggregates subapically. In addition, intestinal biopsy samples showed decreased numbers of lymphocytes. Patient-derived lymphoblasts demonstrated lack of viability and high susceptibility for cell death. Conclusion: STAT1 expression and distribution in the gut of patients with mutations in the DBD are abnormal, suggesting a primary role of STAT1 dysfunction in enterocytes in addition to the secondary effect of aberrant inflammation. Statement of novelty: Colitis associated with STAT1 mutations appears to have unique features distinct from typical inflammatory bowel disease.


  • The effects of STAT1 dysfunction on the gut

    by Cornelia Thoeni, Ellen Hamilton, Abdul Elkadri, Ryan Murchie, Karoline Fiedler, Adi Ovadia, Nigel Sharfe, Bo Yee Ngan, Ernest Cutz, Amit Nahum, et al.

  • Novel de novo mutations of the interleukin-10 receptor gene lead to infantile onset inflammatory bowel disease

    by Cheng Hiang Lee, Peter Hsu, Brigitte Nanan, Ralph Nanan, Melanie Wong, Kevin J. Gaskin, Rupert W. Leong, Ryan Murchie, Aleixo M. Muise, Michael O. Stormon

    Defects in the interleukin 10 (IL-10) signalling pathway have been shown to cause very early onset inflammatory bowel disease (IBD). We report a patient with severe infantile-onset IBD with a compound heterozygous IL-10 receptor alpha subunit (IL-10RA) mutation, one of which was paternally-inherited and the other occurring de novo. Deep sequencing of IL-10, IL-10RA and IL-10 receptor beta subunit (IL-10RB) were performed. Peripheral blood mononuclear cell (PBMC) surface expression of IL-10RA was analysed by flow cytometry. IL-10 signalling pathway was examined by measuring phosphorylated STAT3 in PBMC cultured in the presence of IL-6 or IL-10. We identified a missense mutation in exon 4 of IL-10RA (c.583T>C) in one allele and a nonsense mutation in exon 7 of IL-10RA (c.1368G>T) in the other allele. Neither mutation has been reported previously. The patient has functional IL-10RA deficiency despite normal IL-10RA expression. This represents the first case report of a de novo mutation of IL-10RA that is associated with very early onset severe IBD. Therefore, IL-10 pathway defect should be considered in patients with infantile-onset IBD even if the parents are non-consanguineous.